Literature DB >> 2348190

Low urinary cortisol excretion in patients with posttraumatic stress disorder.

R Yehuda1, S M Southwick, G Nussbaum, V Wahby, E L Giller, J W Mason.   

Abstract

In the present study, we replicated and extended our previous findings of low urinary free-cortisol levels in PTSD. Cortisol was measured in 16 male patients (nine inpatients, seven outpatients) with posttraumatic stress disorder (PTSD) and in 16 nonpsychiatric control subjects. The mean cortisol level in the PTSD group was significantly lower, and the range narrower, than that observed in control subjects. Low cortisol in PTSD did not seem to be related to the presence or absence of major depressive disorder or to overall psychiatric symptomatology as assessed by the sum Brief Psychiatric Rating Scale score. In the outpatient group, there was a relationship between PTSD symptomatology and cortisol levels. The findings suggests a physiological adaptation of the hypothalamic-pituitary-adrenal axis to chronic stress.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2348190     DOI: 10.1097/00005053-199006000-00004

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  97 in total

1.  Physiological differences between burnout patients and healthy controls: blood pressure, heart rate, and cortisol responses.

Authors:  W De Vente; M Olff; J G C Van Amsterdam; J H Kamphuis; P M G Emmelkamp
Journal:  Occup Environ Med       Date:  2003-06       Impact factor: 4.402

Review 2.  Clinical perspectives on neurobiological effects of psychological trauma.

Authors:  Deborah A Weber; Cecil R Reynolds
Journal:  Neuropsychol Rev       Date:  2004-06       Impact factor: 7.444

3.  Spiritual well-being, cortisol, and suicidality in Croatian war veterans suffering from PTSD.

Authors:  Sanea Mihaljević; Bjanka Vuksan-Ćusa; Darko Marčinko; Elvira Koić; Zorana Kušević; Miro Jakovljević
Journal:  J Relig Health       Date:  2011-06

Review 4.  Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications.

Authors:  Anthony S Zannas; Tobias Wiechmann; Nils C Gassen; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2015-08-13       Impact factor: 7.853

Review 5.  Understanding putative risk factors for schizophrenia: retrospective and prospective studies.

Authors:  Suzanne King; David Laplante; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2005-09       Impact factor: 6.186

6.  Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence.

Authors:  Sophie E Holmes; Matthew J Girgenti; Margaret T Davis; Robert H Pietrzak; Nicole DellaGioia; Nabeel Nabulsi; David Matuskey; Steven Southwick; Ronald S Duman; Richard E Carson; John H Krystal; Irina Esterlis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

7.  Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults.

Authors:  Roma A Vasa; Daniel S Pine; Carrie L Masten; Meena Vythilingam; Carlos Collin; Dennis S Charney; Alexander Neumeister; Karin Mogg; Brendan P Bradley; Maggie Bruck; Christopher S Monk
Journal:  Psychopharmacology (Berl)       Date:  2009-03-06       Impact factor: 4.530

8.  Prefrontal Cortex Deep Brain Stimulation Improves Fear and Anxiety-Like Behavior and Reduces Basolateral Amygdala Activity in a Preclinical Model of Posttraumatic Stress Disorder.

Authors:  Roman Reznikov; Francis Rodriguez Bambico; Mustansir Diwan; Roger J Raymond; Mina G Nashed; José N Nobrega; Clement Hamani
Journal:  Neuropsychopharmacology       Date:  2017-09-01       Impact factor: 7.853

Review 9.  Stress and brain atrophy.

Authors:  J Douglas Bremner
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-10       Impact factor: 4.388

10.  Effects of chronic plus acute prolonged stress on measures of coping style, anxiety, and evoked HPA-axis reactivity.

Authors:  Megan K Roth; Brian Bingham; Aparna Shah; Ankur Joshi; Alan Frazer; Randy Strong; David A Morilak
Journal:  Neuropharmacology       Date:  2012-07-25       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.